Share
Michael Dale
Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Michael Dale as Chief Executive Officer and a member of the Board of Directors. Dale succeeds Karen Zaderej, who will remain in an advisory role for nine months to ensure a smooth transition. Additionally, Paul Thomas, a current Board member, will assume the role of Chairman of the Board on the same date.
This leadership transition is part of Axogen’s focus on commercial expansion, driving revenue growth, and achieving sustainable profitability.
"On behalf of the Board of Directors, I offer my deep gratitude to Karen for her invaluable contributions over the past 18 years," said Amy Wendell, Axogen’s Lead Director. "She was integral to the Company’s accomplishments and to the development of the peripheral nerve repair market. We wish her well in her future endeavors."
Wendell added, "We are thrilled to welcome Michael Dale as our new CEO and director. His extensive experience as a global medical technology leader makes him the right choice to advance Axogen’s mission of revolutionizing nerve repair. He brings strategic leadership, innovation, and operational excellence to the table."
Michael Dale, a seasoned medical device executive with over 30 years of experience in cardiovascular, neuromodulation, diabetes, and electrophysiology markets, expressed enthusiasm for his new role. “It is with pride and excitement that I join Axogen," Dale said. "Axogen’s technologies and commitment to restoring peripheral nerve health represent a unique combination of purpose and technological advantage, and I look forward to leading the Company forward."
Dale emphasized his commitment to building upon Axogen’s strong foundation. "To our shareholders and stakeholders, my mission is to establish clear objectives, strategies, and processes to achieve profitability, standard-of-care status, and fulfill our mission."
Paul Thomas, who has been a Board member since 2020, will step into the role of Chairman of the Board. Wendell remarked on his contributions, stating, "Paul has provided invaluable guidance to the Axogen leadership team, and we look forward to his continued leadership in supporting Michael."
Thomas expressed his conviction in Axogen’s future: "I am honored to serve as Chairman at this pivotal time. I am confident in the strong foundation we have built, and I look forward to working closely with Michael, the Board, and the leadership team as we focus on commercial expansion and driving toward sustainable positive cash flow and profitability."
